AI Innovation for Automated Detection and Classification of Osteoporotic Fractures of the Spine in CT Scans | ImageBiopsy Lab launches IB Lab FLAMINGO

ImageBiopsy Lab, a pioneer in medical imaging, introduces IB Lab FLAMINGO at this year’s RSNA conference.  The fully automated software identifies asymptomatic spinal fractures in CT scans. Utilizing the gold standard Genant classification, IB Lab FLAMINGO highlights relevant fractures and empowers proactive treatment for healthcare professionals.

“Our partnership with UCB highlights the potential of leveraging AI for improving care for many diseases, including osteoporosis” explains Richard Ljuhar, CEO at ImageBiopsy Lab.

Understanding the Osteoporosis Challenge

“Together with expert clinicians, UCB developed this deep-learning computational model that can detect vertebral compression fractures on CT scans. ImageBiopsy Lab as a musculoskeletal (MSK) radiology AI company has refined the technology and is now ready to integrate it into clinical care. Given that 80% of fragility fractures today remain undiagnosed and untreated, we’re excited about the potential of IB Lab FLAMINGO to help close the global treatment gap in osteoporosis”, said Jen Timoshanko, Head of Medical Affairs, Bone Health Mission at UCB.

Osteoporosis impacts around 200 million globally, leading to 9 million fragility fractures annually, most of them vertebral (VFs). Its silent progression can cause pain, reduced mobility, and diminished quality of life. Apart from personal suffering, fragility fractures strain global public health systems, escalating treatment costs and mortality rates, posing societal challenges.

“In an ageing society, osteoporosis and its consequences, especially geriatric fractures, challenge patients, physicians, and healthcare systems. IB Lab FLAMINGO’s ability to detect vertebral fractures offers a crucial, automated solution for early risk assessment and targeted treatment in addressing osteoporosis complexities.” Prof. Andreas Kurth, Director of the Center for Orthopaedics and Trauma Surgery at Marienhaus Klinikum Mainz, Germany, expressed the need for a meaningful solution.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version